Translating NMT science into promising new targeted cancer biotherapeutics
Myricx Bio is pioneering N-myristoyltransferase (NMT) inhibitors as a powerful first-in-class antibody-drug conjugate (ADC) payload, which it is applying to a pipeline of proprietary ADC products.
Our NMT Target
Myristoylation is a lipid modification involving the addition of myristic acid, a 14-carbon fatty acid, to the N-terminus of proteins. Catalysed by two enzymes, NMT1 and NMT2, this modification can occur co- or post-translationally. Approx. 1% of proteins in the human genome, which equates to ~150 proteins, are modified by NMT.
Inhibition of NMT is selective and highly efficacious in cancer cells.
Our Biology
Our co-founders and their collaborative teams discovered that NMT plays a vital role in maintaining multiple critical diverse cellular processes in cancer cells. These include: vesicle trafficking, growth factor signaling, cancer cell survival, mitochondrial biogenesis, and cancer cell metabolism.
Our NMTi payload chemistry platform
Multiple series of patent protected NMTis with a range of potency underpin our payload chemistry platform. These payloads form the backbone of our ADCs, are compatible with a range of linkers, and are easy to conjugate.
We are developing a pipeline of first-in-class NMTi-ADCs that target clinically validated cancer antigens towards the clinic.
